Improving the Therapeutic Ratio of Proton Radiation Therapy
提高质子放射治疗的治疗率
基本信息
- 批准号:8336786
- 负责人:
- 金额:$ 4.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-21 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAdverse effectsAnatomic SitesAnesthesia proceduresBAY 54-9085Cancer PatientChildChildhoodChildhood MedulloblastomasChildhood RhabdomyosarcomaClinicalClinical ResearchClinical TrialsComplexCorrelative StudyDevicesDiseaseDoseEffectivenessGoalsHepaticInvestigationLengthLiver neoplasmsMalignant NeoplasmsMorbidity - disease rateNeutronsNon-Small-Cell Lung CarcinomaNormal tissue morphologyOperative Surgical ProceduresOutcomeParanasal Sinus NeoplasmsPatientsPhasePhotonsPhysicsPositioning AttributeProtocols documentationProton RadiationProtonsPublic HealthQuality-of-Life AssessmentRadiationRadiation therapyRelative (related person)ResearchRhabdomyosarcomaRiskScanningSinusTestingTherapeuticTherapeutic StudiesToxic effectTranslatingTumor TissueUnresectableVertebral columnX-Ray Computed Tomographychemotherapyclinical research sitecohorthigh riskimprovedirradiationmedulloblastomaphase 2 studyprospectiveproton beamrandomized trialresponsesarcomaskull basetooltreatment planningtumor
项目摘要
Protons have a physical dose advantage over photons (x-rays), the most commonly used type of
radiation therapy for cancer patients, because they do not exit beyond the tumor target and thus irradiate
less normal tissue. Irradiation of normal tissue yields no possible benefit for the patient; it can only increase
the risk of treatment related side effects during and long after the end of treatment. While proton radiation
therapy has been used in selective clinical sites with significant improvements in clinical outcome, we believe
that research into better control of the finite range of the proton in the patient can yield additional clinical
gains. The major objective of this project, Improving the Therapeutic Ratio of Proton Radiation Therapy in
Challenging Clinical Sites, is to perform clinical trials employing improved control of the proton range in
challenging clinical scenarios. We believe that these research advances should translate into further
improvement in outcome in not only these particular diseases, but at multiple other anatomic sites where
proton radiation therapy is increasingly being employed. The potential impact for public health is higher
cancer cure rates and/or reduced treatment side effects, particularly in children, who are at the highest risk of
late radiation therapy-induced side effects, which can be reduced with the use of protons.
The specific aims are to conduct phase II clinical studies in patients with unresectable liver tumors,
pediatric medulloblastoma and rhabdomyosarcoma, spine and skull base sarcomas, and paranasal sinus
tumors in which we will (1) use the end of range of the proton more effectively, (2) investigate the clinical use
of magnetically scanned proton beams and intensity-modulated proton therapy, (3) confirm the tolerability
and effectiveness of hypofractionated radiation dose escalation for unresectable liver tumors, (4) critically
assess the importance of an adaptive proton radiation therapy strategy in response to tumor and normal
tissue responses to radiation therapy in one anatomic site, and (5) compare treatment-related morbidity with
photons and protons in these selected pediatric malignancies and in adult paranasal sinus tumors. The
physical tools necessary to achieve these clinical goals will be investigated in Projects 3 and 4. The initial
use of many of these physical tools in Project 2 will be important for their later use in Project 1, Proton Dose
Escalation and Proton vs. Photon Randomized Trials for Non-Small Cell Lung Cancer.
质子比光子(X射线)具有物理剂量优势,光子是最常用的放射性核素类型。
癌症患者的放射治疗,因为它们不会超出肿瘤靶区,
正常组织较少。正常组织的辐射对患者没有可能的益处;它只能增加
治疗期间和治疗结束后很长时间内治疗相关副作用的风险。虽然质子辐射
我们相信,在选择性的临床部位使用这种疗法,临床结果得到了显著改善,
研究更好地控制患者体内质子的有限范围可以产生额外的临床效果,
收益.本计画之主要目的为提高台湾地区质子放射治疗之治疗率,
临床研究中心,是进行临床试验,采用改进的质子范围控制,
具有挑战性的临床场景。我们认为,这些研究进展应该转化为进一步的研究。
不仅在这些特定疾病中,而且在多个其他解剖部位,
质子放射治疗正越来越多地被采用。对公众健康的潜在影响更大
癌症治愈率和/或减少治疗副作用,特别是在儿童中,他们是最高风险的
晚期放射治疗引起的副作用,这可以通过使用质子来减少。
具体目标是在不可切除的肝肿瘤患者中进行II期临床研究,
小儿髓母细胞瘤和横纹肌肉瘤,脊柱和颅底肉瘤,鼻窦
我们将(1)更有效地使用质子范围的末端,(2)研究
磁扫描质子束和强度调制质子治疗,(3)确认耐受性
大分割放射剂量递增治疗不可切除的肝肿瘤的有效性,(4)严重
评估适应性质子放射治疗策略对肿瘤和正常
一个解剖部位对放射治疗的组织反应,以及(5)比较治疗相关的发病率,
光子和质子在这些选定的儿科恶性肿瘤和成人鼻窦肿瘤。的
将在项目3和4中研究实现这些临床目标所需的物理工具。初始
在项目2中使用这些物理工具中的许多工具对于它们以后在项目1中的使用将是重要的,质子剂量
非小细胞肺癌的递增和质子与光子随机试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS F DELANEY其他文献
THOMAS F DELANEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS F DELANEY', 18)}}的其他基金
Improving the Therapeutic Ratio of Proton Radiation Therapy
提高质子放射治疗的治疗率
- 批准号:
7523008 - 财政年份:2008
- 资助金额:
$ 4.77万 - 项目类别:
Improving the Therapeutic Ratio of Proton Radiation Therapy
提高质子放射治疗的治疗率
- 批准号:
8736216 - 财政年份:1997
- 资助金额:
$ 4.77万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 4.77万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Studentship